But it's especially frustrating when one nostril is perfectly clear and the other is blocked. It can happen when you're sick ...

Do any of these symptoms sound familiar: Stuff or Runny Nose? Headaches? Sinus Pressure? Snoring? Many of you probably recognize all of them. But, did you realize any attempt to self-medicate will ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

If nasal congestion persists, pus can accumulate in the sinuses and inflammation can spread If inflammation continues, polyps can also develop in the sinuses I thought, if this continues ...

Dr. Albritton is a resident physician and Dr. Kingdom is Assistant Professor in the Department of Otolaryngology at Emory University School of Medicine, Atlanta, Ga. Albritton FD, Kingdom TT.

Both trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score at 52 weeks and a change from baseline in mean nasal obstruction score from weeks 49 to 52.

The makers of a nasal spray launched last year by start-up Akita Biosciences have pulled back the curtain on how their product works (Adv. Mater. 2024, DOI: 10.1002/adma.202406348). The company ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...